425: Alumis and ACELYRIN Amend Merger Agreement, Adjusting Stock Ownership

Alumis and ACELYRIN have amended their merger agreement, adjusting the stock exchange ratio to reflect current market conditions and investor expectations.

Summary

• Alumis and ACELYRIN have amended their previously announced merger agreement.
• The key change involves the stock exchange ratio, where ACELYRIN stockholders will now receive 0.4814 shares of Alumis common stock for each ACELYRIN share.
• As a result, Alumis stockholders will own approximately 52% of the combined company, while ACELYRIN stockholders will own about 48% on a fully diluted basis.
• All other terms of the original merger agreement from February 6, 2025, remain the same.
• The companies still anticipate closing the transaction in the second quarter of 2025, with Special Meetings scheduled for May 13, 2025.
• The combined company is expected to have a pro forma cash position of approximately $737 million as of December 31, 2024.
• This financial strength is intended to support the advancement of their pipeline and build commercial capabilities.

Sentiment

Score: 7

Explanation: The sentiment is cautiously optimistic. While the amendment suggests some challenges, the companies express confidence in the merger's merits and the combined entity's future prospects. The pro forma cash position is a positive sign.

Positives

• The amended terms are believed to be the best path forward given current market conditions.
• The combined company will have enhanced financial flexibility with a pro forma cash position of approximately $737 million.
• The merger is expected to create value for both sets of stockholders.
• The companies reaffirm their belief in the merits of the transaction.

Negatives

• The adjustment of the stock exchange ratio indicates a potential decrease in the perceived value of ACELYRIN relative to Alumis.
• The need for amended terms suggests initial expectations were not aligned with market realities.

Risks

• The transaction may not be completed in a timely manner or at all.
• Required approvals, including stockholder approvals, may not be received.
• The announcement of the merger could negatively impact the companies' ability to retain key personnel and maintain relationships.
• The merger could divert management's attention from ongoing business operations.
• Legal proceedings related to the merger could arise.
• The anticipated benefits and synergies of the merger may not be fully realized.
• Integration of ACELYRIN's operations may not occur as anticipated.
• There are risks related to the value of Alumis securities to be issued in the transaction.
• Delays in initiating, enrolling, or completing preclinical studies and clinical trials are possible.

Future Outlook

The companies expect to close the transaction in the second quarter of 2025 and believe the combined entity will have enhanced financial flexibility to advance their pipeline and build commercial capabilities.

Management Comments

• We believe the revised terms are the best path forward and enable enhanced value creation opportunities for our respective stockholders.
• We continue to firmly believe in the merits of the transaction.

Industry Context

Mergers and acquisitions in the biotech industry are common, often driven by the desire to consolidate pipelines, share resources, and achieve greater market presence. This amendment reflects the sensitivity of deal terms to market conditions and investor sentiment, a common factor in such transactions.

Comparison to Industry Standards

• Deal renegotiations are not uncommon in the biotech industry, especially when market conditions shift between the initial announcement and the anticipated closing date.
• The adjusted ownership split reflects a recalibration of the relative value of each company, similar to what has been observed in other biotech mergers facing regulatory or clinical setbacks.
• Comparable companies that have adjusted merger terms include [hypothetical example] Company A and Company B, who revised their agreement due to clinical trial data.

Stakeholder Impact

• Shareholders of both Alumis and ACELYRIN will be impacted by the adjusted stock ownership and the potential value creation of the combined company.
• Employees of both companies may experience uncertainty during the merger process.
• The combined company aims to advance its pipeline and build commercial capabilities, potentially benefiting patients.

Next Steps

• Alumis will file a registration statement on Form S-4 with the SEC, including a joint proxy statement/prospectus.
• The joint proxy statement/prospectus will be delivered to stockholders of Alumis and ACELYRIN.
• Stockholder votes will be held at Special Meetings scheduled for May 13, 2025.
• The transaction is expected to close in the second quarter of 2025, pending regulatory and stockholder approvals.

Key Dates

Keywords

merger, Alumis, ACELYRIN, stockholders, agreement, transaction, amendment